Paradigm Biocapital Advisors LP Cogent Biosciences, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,609,762 shares of COGT stock, worth $35.8 Million. This represents 1.79% of its overall portfolio holdings.
Number of Shares
4,609,762
Previous 3,624,342
27.19%
Holding current value
$35.8 Million
Previous $30.6 Million
62.95%
% of portfolio
1.79%
Previous 1.24%
Shares
3 transactions
Others Institutions Holding COGT
# of Institutions
172Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$81.3 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$71.7 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$58.5 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$56.6 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$54 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $510M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...